Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > OxyContin Patent Allegations Dismissed Against Purdue

Drug Industry Daily

March 10, 2010 | Vol. 9 No. 47

OxyContin Patent Allegations Dismissed Against Purdue

Six plaintiffs have dropped accusations that Purdue Pharma prevented generic competition for its painkiller OxyContin through misrepresentations to the PTO and sham patent litigation.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Reveals First Generic Challenge to Celgene’s Cancer Drug Revlimid Watson False Marking Suit Is Latest in a Worrying Trend for Drugmakers Federal Court Refuses Sanofi Motion to Block Sale of Generic Lovenox CMS Paid $43 Million for Drugs Considered Less-Than-Effective

Home
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.